Compare · MASS vs TMO
MASS vs TMO
Side-by-side comparison of 908 Devices Inc. (MASS) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MASS and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $257.53B, about 524.0x MASS ($491.5M).
- TMO has been more active in the news (7 items in the past 4 weeks vs 5 for MASS).
- TMO has more recent analyst coverage (25 ratings vs 7 for MASS).
- Company
- 908 Devices Inc.
- Thermo Fisher Scientific Inc
- Price
- -
- -
- Market cap
- $491.5M
- $257.53B
- 1M return
- -
- +4.77%
- 1Y return
- -
- +28.01%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 5
- 7
- Recent ratings
- 7
- 25
908 Devices Inc.
908 Devices Inc. develops and sells measurement devices for chemical and biochemical analysis in North America, Europe, the Middle East, Africa, and the Asia Pacific. It offers handheld and desktop mass spectrometry (Mass Spec) devices for the point-of-need applications in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest MASS
- SEC Form 4 filed by 908 Devices Inc.
- SEC Form 4 filed by 908 Devices Inc.
- SEC Form 144 filed by 908 Devices Inc.
- Large owner Awm Investment Company, Inc. sold $207,322 worth of shares (18,000 units at $11.52) (SEC Form 4)
- Large owner Awm Investment Company, Inc. sold $283,876 worth of shares (25,000 units at $11.36) (SEC Form 4)
- SVP, Sales & Product Marketing Kenneweg John sold $280,070 worth of shares (27,656 units at $10.13) as part of a pre-agreed trading plan and exercised 27,656 shares at a strike of $0.96 (SEC Form 4)
- Canaccord Genuity initiated coverage on 908 Devices with a new price target
- 908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium
- Chief Financial Officer Griffith Joseph H. Iv sold $125,476 worth of shares (11,459 units at $10.95) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 121,497 units (SEC Form 4)
- SEC Form 144 filed by 908 Devices Inc.
Latest TMO
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- SEC Form 4 filed by Director Keith R. Alexandra
- Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
- Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
- Thermo Fisher upgraded by UBS with a new price target
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)